6FN Stock Chart & Stats
€0.06
>-€0.01(-25.00%)
At close: 4:00 PM EST
€0.06
>-€0.01(-25.00%)
Day’s Range― - ―
52-Week Range€0.03 - €0.12
Previous CloseN/A
Volume0.00
Average Volume (3M)8.58K
Market Cap
€17.06M
Enterprise Value€278.94M
Total Cash (Recent Filing)€342.00K
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta1.68
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding245,976,150
10 Day Avg. Volume650
30 Day Avg. Volume8,579
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)-31.79
Price to Sales (P/S)13.71
P/FCF Ratio-3.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)€2.22M
Bulls Say, Bears Say
Bulls Say
Platform Drug-delivery TechnologyKlaria's proprietary mucoadhesive oral film platform is a durable strategic asset: it can be applied across indications to deliver rapid systemic uptake, creating potential product pipeline leverage, licensing opportunities and differentiation versus injectable or oral-solid competitors.
Flexible Commercialization ModelA dual go-to-market approach—direct commercialization or partnership—reduces execution risk and capital intensity. Structurally, it allows Klaria to scale selectively, partner for costly late‑stage development or commercialization, and capture value while limiting upfront commercialization spend.
Reported Reduction In Debt By 2025Elimination of reported debt in 2025 materially lowers interest and refinancing obligations and modestly improves solvency prospects. Over the medium term, lower gross leverage can expand strategic options and reduce default risk compared with prior high-leverage years.
Bears Say
Negative Shareholders' EquityNegative equity is a structural red flag indicating cumulative losses or dilution; it constrains access to debt markets, can trigger covenant or regulatory issues, and typically forces reliance on dilutive equity raises, undermining long‑term financial flexibility and strategic options.
Persistent And Rising Cash BurnChronic negative operating cash flow and a sharp increase in 2025 cash burn create sustained funding pressure. Over 2–6 months this elevates refinancing and dilution risk, may delay R&D or trials, and forces management to secure external capital under potentially unfavorable terms.
Persistent Losses And Weak Revenue TrendsConsistent losses and a severely negative net margin indicate structural inability to convert revenue into profitability. Declining revenue in 2025 versus 2024 signals execution or market uptake challenges, increasing the need for sustained investment without near‑term evidence of margin recovery.
6FN FAQ
What was Klaria Pharma Holding AB’s price range in the past 12 months?
Klaria Pharma Holding AB lowest stock price was €0.03 and its highest was €0.12 in the past 12 months.
What is Klaria Pharma Holding AB’s market cap?
Klaria Pharma Holding AB’s market cap is €17.06M.
When is Klaria Pharma Holding AB’s upcoming earnings report date?
Klaria Pharma Holding AB’s upcoming earnings report date is Aug 27, 2026 which is in 48 days.
How were Klaria Pharma Holding AB’s earnings last quarter?
Klaria Pharma Holding AB released its earnings results on May 29, 2026. The company reported -€0.003 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.003.
Is Klaria Pharma Holding AB overvalued?
According to Wall Street analysts Klaria Pharma Holding AB’s price is currently Overvalued.
Does Klaria Pharma Holding AB pay dividends?
Klaria Pharma Holding AB does not currently pay dividends.
What is Klaria Pharma Holding AB’s EPS estimate?
Klaria Pharma Holding AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Klaria Pharma Holding AB have?
Klaria Pharma Holding AB has 245,976,150 shares outstanding.
What happened to Klaria Pharma Holding AB’s price movement after its last earnings report?
Klaria Pharma Holding AB reported an EPS of -€0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Klaria Pharma Holding AB?
Currently, no hedge funds are holding shares in DE:6FN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Klaria Pharma Holding AB
Klaria Pharma Holding AB (publ.) functions as a pharmaceutical enterprise, active both in Sweden and across global territories. Its current portfolio features Sumatriptan for migraine management and Midazolam for combating acute epileptic seizures. Within its pipeline, Klaria is developing Epinephrine/Adrenaline to address severe allergic responses, Naloxone for reversing opioid overdoses, and Ketamine for applications in acute pain and mood disorders. Moreover, the company is actively involved in bringing cannabis/cannabinoid products, including THC and CBD, to market for medical and recreational purposes. Established in 2014, Klaria is headquartered in Uppsala, Sweden.